342 related articles for article (PubMed ID: 27940449)
1. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract][Full Text] [Related]
3. Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
Masunaga N; Kagara N; Motooka D; Nakamura S; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2018 Jan; 167(1):49-58. PubMed ID: 28905136
[TBL] [Abstract][Full Text] [Related]
4. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
[TBL] [Abstract][Full Text] [Related]
5. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
[TBL] [Abstract][Full Text] [Related]
7. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
8. Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study.
Ritter M; Paradiso V; Widmer P; Garofoli A; Quagliata L; Eppenberger-Castori S; Soysal SD; Muenst S; Ng CKY; Piscuoglio S; Weber W; Weber WP
Clin Breast Cancer; 2020 Oct; 20(5):413-421.e1. PubMed ID: 32650988
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
10. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.
Bechmann T; Andersen RF; Pallisgaard N; Madsen JS; Maae E; Jakobsen EH; Bak Jylling AM; Steffensen KD; Jakobsen A
J Cancer Res Clin Oncol; 2013 Jun; 139(6):995-1003. PubMed ID: 23479212
[TBL] [Abstract][Full Text] [Related]
11. Detection fidelity of AR mutations in plasma derived cell-free DNA.
Goldstein A; Toro PV; Lee J; Silberstein JL; Nakazawa M; Waters I; Cravero K; Chu D; Cochran RL; Kim M; Shinn D; Torquato S; Hughes RM; Pallavajjala A; Carducci MA; Paller CJ; Denmeade SR; Kressel B; Trock BJ; Eisenberger MA; Antonarakis ES; Park BH; Hurley PJ
Oncotarget; 2017 Feb; 8(9):15651-15662. PubMed ID: 28152506
[TBL] [Abstract][Full Text] [Related]
12. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
16. An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA.
Vitale SR; Sieuwerts AM; Beije N; Kraan J; Angus L; Mostert B; Reijm EA; Van NM; van Marion R; Dirix LY; Hamberg P; de Jongh FE; Jager A; Foekens JA; Vigneri P; Sleijfer S; Jansen MPHM; Martens JWM
J Mol Diagn; 2019 Jan; 21(1):123-137. PubMed ID: 30296589
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
[TBL] [Abstract][Full Text] [Related]
18. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
20. Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.
Gyanchandani R; Kvam E; Heller R; Finehout E; Smith N; Kota K; Nelson JR; Griffin W; Puhalla S; Brufsky AM; Davidson NE; Lee AV
Sci Rep; 2018 Nov; 8(1):17313. PubMed ID: 30470782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
